Tailwinds for MIDD: EMA, FDA, and a Converging Regulatory Landscape
October 29, 2026 - 11:00 PM – 2:00 PM
Chara LitouSeptember 9, 2026
From Models to Decisions: Building MIDD Readiness in the Era of ICH M15
Build the governance, capabilities, and cross-functional alignment that turn MIDD evidence into decision-ready evidence under…
Rik de GreefSeptember 9, 2026
A glimpse into the future of model-informed drug discovery and development
Explore the future of Model-Informed Drug Development (MIDD), including advances in pharmacometrics, PBPK, QSP, precision…
CertaraAugust 28, 2026
Refinement of Operating Characteristics for Model-Based TGI Metrics Decision Support to Ungate a Pivotal Trial in Oncology
Explore how model-based tumor growth inhibition metrics can support earlier Go/No-Go decisions and pivotal trial…
CertaraAugust 28, 2026
De-Risking Phase 3 Rheumatoid Arthritis Trials with Model-Based Meta-Analysis (MBMA)
Learn how Model-based meta-analysis (MBMA) helped optimize Phase 3 trial design, dose selection, and development…
Danielle PillsburyAugust 28, 2026
The five drug development questions that bring sponsors to pharmacometrics
Sponsors rarely come to pharmacometrics because they need a model. They come with a development…
Rik de GreefAugust 24, 2026
Beyond Trial and Error: Model-Informed Formulation Development in Practice
Learn how model-informed formulation development and PBPK modeling can guide formulation strategy, bioequivalence, and biowaiver…
Siri Kalyan ChirumamillaAugust 24, 2026
Model-Based Meta-Analysis (MBMA): Real-World Examples
See real-world examples of how model-based meta-analysis (MBMA) uses existing clinical evidence to predict trial…
CertaraAugust 24, 2026
MBMA data curation: How AI and expert meta-analysts get it right, fast
In MBMA, the data layer is the real bottleneck. See how AI and expert meta-analysts…
Matt Zierhut, PhD MBAAugust 14, 2026
